Traditional pathological examinations of tau burden suffer from the limitations that very small sections of tissue are sampled and only one half of the brain is typically sampled, limiting the evaluation of distribution across the whole brain.
Positron emission tomography (PET) ligands, such as [ 18 F]AV-1451, have recently been developed that specifically target tau proteins in the brain. 5, 6 This ligand was originally developed and optimized to target tau proteins present in Alzheimer's disease, and the ligand shows strong medial temporal and cortical binding in patients with Alzheimer's dementia. 7, 8 However, this development also opens up exciting possibilities for the in vivo assessment of tau pathology in PSP. Tau-PET imaging could allow the assessment of the distribution of tau pathology, spread of tau pathology over time, and the assessment of how tau pathology is associated with clinical measures collected at the same point in time. Understanding the natural biology of tau deposition in PSP will ultimately be critical to determine how tau-PET measurements should be used as outcome measures for treatment trials and to aid diagnosis. However, an essential first step is to determine how tau-PET imaging behaves in patients with PSP.
The aim of our study was to assess tau-PET imaging using [ 18 F]AV-1451 in a group of PSP patients to determine whether uptake can be observed when compared with age-matched healthy controls and to characterize the regional distribution of tau-PET uptake in PSP. We also aimed to determine whether the [ 18 F]AV-1451 signal correlated to clinical disease severity at the time of tau-PET imaging, and how the regional distribution in PSP compares to the distribution in patients with amnestic Alzheimer's dementia.
Methods Participants
A total of 10 patients who presented with a Richardson's syndrome and fulfilled clinical criteria for probable PSP 3 underwent tau-PET imaging for this study. All of the patients with PSP who were evaluated in the Department of Neurology, Mayo Clinic, between February 20, 2015 , and May 26, 2016 , were consecutively recruited into a National Institutes of Health-funded prospective longitudinal PSP study by a neurodegenerative specialist and PSP expert (KAJ). Patients were included in the study if they met criteria for probable PSP, had symptoms for 5 years, and were able to ambulate independently. Patients meeting criteria for possible PSP, 3 progressive akinesia with gait freezing, 9 or PSP parkinsonism 10 were excluded from the study. All patients underwent clinical and neurological examination and completed standardized and validated testing. All PSP patients completed the PSP rating scale (PSPRS) 11 The study was approved by the Mayo institutional review board. All participants consented to research. 
Tau-PET Analysis
nucleus of the cerebellum was manually drawn on the atlas using a T2*-weighted template for reference. Voxels containing the dentate nucleus of the cerebellum were removed from all other cerebellar ROIs. Left and right hemisphere structures were combined for each ROI. Median [
18 F]AV-1451 uptake in each ROI was divided by median uptake in cerebellar crus grey matter to create standard uptake ratios (SUVr). There was no difference in raw [ Voxel-level group comparisons of [ 18 F]AV-1451 uptake was also performed using SPM5. All MPRAGE scans were spatially normalized to a customized template 17 and segmented using the unified segmentation model, 18 followed by the hidden Markov random field clean-up step. The [ 18 F]AV-1451 images were coregistered to the participant's MPRAGE using 6 degrees-of-freedom registration. The AAL atlas was propagated to native MPRAGE space. All voxels in the [ 18 F]AV-1451 image were divided by median uptake in cerebellar crus gray matter to create SUVr images. These images were then normalized to the customized template using the normalization parameters from the MPRAGE normalization. Voxel-level comparisons were performed using 2-sided t tests in Statistical Parametric Mapping (SPM5) (www.fil.ion.ucl.ac.uk/ SPM), with results assessed at P < .05 after correction for multiple comparisons using the false discovery rate correction. Age and gender were included in the analysis as covariates.
FIG. 2.
Voxel-level group comparisons of tau-PET uptake. Regions that showed a greater signal in PSP patients when compared with controls and Alzheimer's dementia are shown on coronal slices through the template (with Y coordinates provided), and regions that showed a greater uptake in Alzheimer's dementia are shown on 3-dimensional surface renderings of the brain. The results are shown after partial volume correction and corrected for multiple comparisons at P <.05 using the false discovery rate correction. R, right; L, left.
Statistics
For the ROI-level analysis, differences in the 49 ROIs between PSP and both controls and Alzheimer's dementia were tested using 2-sample Wilcoxon/MannWhitney tests and summarized by the area under the receiver operating characteristic curve (AUROC), which can be interpreted as a nonparametric measure of effect size, that is, groupwise differences, independent of the underlying scale of measurement. In general, the higher the AUROC estimates, the better the discrimination between groups. These analyses were not adjusted for multiple comparisons because adjustment would increase the type II errors for associations that are not null. Not adjusting for multiple comparisons has been advocated because it will result in fewer errors in interpretation when the data are not random numbers but actual observations on nature. 19 Adjusting our data could therefore result in missing important findings, particularly in this exploratory analysis. We note that in the SPM5 analysis we use false discovery rate correction because of the large scale of the hypothesis testing. We also performed partial correlation analyses using Spearman rank correlations adjusted for age and gender between PSPRS and tau SUVr values in regions where the P values from the 2-sample Wilcoxon/Mann-Whitney tests between PSP and controls were less than .05. Our analyses were performed using PVC tau-PET images as well as repeated using non-PVC tau-PET images because it is currently unclear which method is the most FIG. 3 . Individual tau-PET images for the 10 PSP patients, 2 healthy controls, and 2 Alzheimer's dementia patients. Coronal images at the level of the dentate nucleus of the cerebellum, midbrain, and basal ganglia as well as an axial image at the level of the midbrain are shown. All images are shown on the same standard uptake ratio scale (0-3). In the box plots, the upper whisker extends from the hinge to the highest value that is within 1.5 3 interquartile range of the hinge, where the interquartile range is the distance between the first and third quartiles. Inf, inferior; mid, middle; sup, superior; tri, triangularis; oper, opercularis; orb, orbital; ant, anterior; post, posterior.
appropriate for tau-PET imaging. 7, 8 All analyses were performed with R statistic software (version 3.1.3; R Foundation for Statistical Computing, Vienna, Austria).
Results

Demographics
The median age at onset for all 10 PSP patients was 63 years (range 57-65), median age at examination 65 years (range 60-69), and median disease duration 3.5 years (range 2.5-4.0). Of the 10 PSP patients, 6 were women (60%). At the time of [ 18 F]AV-1451 tau-PET, all PSP patients were essentially cognitively intact with a median MoCA score of 27 (range [25] [26] [27] [28] [29] [30] , and all were of moderate severity with a median PSPRS score of 37 (range 32-39).
PSP Patients Compared With Controls
In the ROI-level analysis (Fig. 1) , an elevated tau-PET signal was observed in the PSP patients when compared with controls in the midbrain, pallidum, thalamus, supplementary motor area, dentate nucleus of the cerebellum, precentral cortex, frontal inferior opercularis, caudate nucleus, and middle frontal gyrus. Of these regions, only the pallidum, dentate nucleus of the cerebellum, thalamus, and midbrain showed a significantly elevated signal in PSP when compared with controls in the non-PVC comparison.
In the voxel-level analysis (Fig. 2) , the PSP patients showed an elevated tau-PET signal bilaterally in the dentate nucleus of the cerebellum, midbrain, thalamus, subthalamic nucleus, pallidum, caudate nucleus, and supplementary motor areas when compared with controls. All regions, except for the supplementary motor area, were also identified in the non-PVC comparison.
Individual tau-PET images from the 10 PSP patients are shown in Figure 3 . Some variability was observed across PSP patients, although most patients showed greater signal in the dentate nucleus of the cerebellum, midbrain, thalamus, subthalamic nucleus, and basal ganglia, compared to cortical regions. Elevated signal in these regions was also observed in some of the healthy controls (Fig. 3) .
PSP Patients Compared With Alzheimer's Dementia
In the ROI-level analysis (Fig. 4) , median tau-PET signal was greater in PSP when compared with Alzheimer's dementia in the dentate nucleus of the cerebellum, pallidum, midbrain, thalamus, and pons, although the only differences to reach significance were the dentate nucleus of the cerebellum and the pallidum. The tau-PET signal in all of the rest of the ROIs was greater in Alzheimer's dementia than in the PSP, with the most striking difference observed in the medial and lateral parietal regions. These results were the same in the non-PVC comparisons.
In the voxel-level analysis (Fig. 2) , the PSP patients showed a greater tau-PET signal in the midbrain, dentate nucleus of the cerebellum, thalamus, and pallidum when compared with the Alzheimer's dementia patients. The Alzheimer's dementia patients showed greater tau-PET signal throughout the temporoparietal, FIG. 5 . Scatterplots between PSP rating scales (PSPRS) and tau standard uptake ratio (SUVr) values with partial correlation estimates and P value. Inf, inferior; mid, middle; oper, opercularis.
frontal, and occipital cortices when compared with controls and PSP patients. These results were the same in the non-PVC comparisons. A widespread cortical tau-PET signal can be seen in the 2 Alzheimer's dementia patients shown in Figure 3 .
PSPRS Correlations in PSP
Correlations were identified between PSPRS scores and [ 
Discussion
We demonstrated that an elevated [ 18 F]AV-1451 signal was observed in PSP patients when compared with age-matched controls. The pattern of elevated signal was relatively focal, involving the pallidum, dentate nucleus of the cerebellum, midbrain, thalamus, caudate nucleus, and frontal lobe; all regions that typically show tau deposition at autopsy in PSP patients.
The regional [
18 F]AV-1451 signal elevation in PSP patients was particularly striking in the subcortical, cerebellar, and brain stem regions when compared with controls and would be consistent with a recently published case report that also found elevated [ 18 F]AV-1451 uptake in PSP patients, largely in the pallidum and midbrain. 20 These regions also showed a greater signal in PSP when compared with the Alzheimer's dementia patients, suggesting a distinct pattern specific for PSP, at least when compared with Alzheimer's dementia patients and controls. However, it should be noted that an increased signal in these regions may be difficult to identify in individual PSP patients because many of these subcortical structures showed an age-associated elevated signal in the healthy controls (Fig. 3) as others have noted. 8, 21 Our group-level analysis controlled for this confounder by comparing our PSP patients to healthy controls and Alzheimer's dementia patients that were well matched by age, and our PSP patients indeed showed a higher signal than what would be expected for their age. The overlap still observed between PSP patients and the age-matched controls could, however, likely limit the diagnostic value of these regional [
18 F]AV-1451 measures in individual patients. In addition to the focal pattern of subcortical tau-PET signal, we did observe involvement of some cortical regions, particularly the supplementary motor area and middle and inferior frontal lobes. However, these regions only showed significant signal increase in the analysis that used partial volume correction; no cortical regions were identified in the images that had not been corrected for partial volume averaging. It is, therefore, possible that the presence of atrophy in the frontal lobe reduced the tau-PET signal in the raw images. The alternative explanation would be that the partial volume correction over inflated signal in regions that lie close to the cerebrospinal fluid boundary, such as cortical regions and the caudate nucleus. Further work will be needed to analyze the value of partial volume correction in tau-PET data. Nevertheless, it is clear that the cortical signal was less than that observed in the subcortical, brain stem, and cerebellar regions. The majority of the cortical regions did not survive correction for multiple comparisons in the voxel-level analyses, either with or without partial volume correction, and would likely not survive correction at the region level. This may suggest that tau pathology spreads from the subcortical regions to cortex; although longitudinal studies will be needed to investigate this hypothesis.
A greater tau-PET signal in the dentate nucleus of the cerebellum, midbrain, thalamus, supplementary motor area, and inferior and middle frontal gyri also correlated with greater impairment on the PSPRS in the PSP patients. The presence of tau pathology in these regions may, therefore, be particularly important for the development of the clinical features of PSP. This adds to data from previous studies that have shown a relationship between neurodegeneration of the dentatorubrothalamic white matter tract 22 and connectivity in the supplementary motor area and disease severity in PSP. 23, 24 The dentatorubrothalamic tract connects the dentate nucleus of the cerebellum to the thalamus via the midbrain, with projections from the thalamus then terminating in the premotor cortex. We could, therefore, hypothesize that the clinical features of PSP may develop as a result of a breakdown in this functional network of regions along the dentatorubrothalamic tract, 22 which in turn may result from the deposition of tau in these regions. We could also hypothesize that the lack of correlations with PSPRS in the basal ganglia structures may be because these regions are not central to this dentatorubrothalamic network. A note of caution, however, is that the correlations would be affected by the inclusion of different PSP clinical variants as well as the spread of disease severities present in the cohort.
Both the subcortical and cortical regions identified in this study do typically show neurodegeneration and tau pathology at autopsy. 2, 25 However, we must be cautious in the pathological interpretation of these 21, 26, 27 Our findings are not inconsistent with this, given that the magnitude of binding (ie, SUVrs) in the individual PSP patients was relatively low compared to the striking uptake observed in the cortex in the patients with Alzheimer's dementia. These findings are consistent with either the ligand being more specific to the 3 1 4R isoform that characterizes Alzheimer's disease associated tau than the 4R tau isoform that characterizes PSP, or the ligand being more specific to paired helical filaments associated with Alzheimer's dementia versus straight filaments associated with PSP. 21, 27 Another possibility for the difference in uptake could be the relative amount of mature versus early neurofibrillary tangles that are present in Alzheimer's disease versus PSP given that Alzheimer's disease has a higher ratio of mature/early tangles when compared with PSP. Although some mild [ 18 F]AV-1451 uptake was observed in the cortical regions in PSP, the degree of cortical uptake was higher in Alzheimer's dementia when compared with PSP across all cortical ROIs, but particularly in the medial and lateral parietal regions. Elevated cortical uptake in Alzheimer's dementia agrees with previous studies. 7, 8, 29 Perhaps surprisingly, we observed higher SUVr values in the neocortex when compared with the medial temporal lobe regions, particularly the hippocampus, in our Alzheimer's dementia cohort. This may, however, reflect the young age of our Alzheimer's dementia cohort because greater tau deposition in the cortex compared with the hippocampus at autopsy has been associated with younger age in Alzheimer's disease. 30, 31 A similar predominance of cortical uptake when compared with the hippocampus has been observed in a tau-PET study using [ 18 F]AV-1451 that also had a relatively young Alzheimer's dementia cohort 8 , and another tau-PET study found a greater cortical burden in youngonset when compared with old-onset Alzheimer's dementia. 7 A strength of our study is the homogeneity of the cohort, with all patients presenting with Richardson's syndrome, the most common variant of PSP, and all fulfilling criteria for probable PSP. A diagnosis of probable PSP has a high sensitivity and specificity for pathological PSP. 32, 33 Our findings may not, however, generalize to patients with other clinical variants of PSP 34 , or to PSP patients with a different degree of disease severity. Given the weak binding of [ 18 F]AV-1451 to 4R tau in PSP in autoradiographic studies and the lack of other published PET studies on [ 18 F]AV-1451 in PSP, we must be cautious in drawing conclusions about the utility of this ligand in diagnosis, or as a biomarker, in PSP. Our data show that it may hold some promise as a research tool, although a ligand with more robust binding may be more ideal. There are also some potential issues with the [
18 F]AV-1451 ligand to consider. One issue is the fact that an elevated signal in some of the PSP-related structures, such as the basal ganglia, midbrain, and dentate nucleus of the cerebellum, can also be seen in healthy controls, and may be related to the presence of iron pigment or neuromelanin. 21 Another issue to take into account is that [
18 F]AV-1451 off-target binding to neuromelanin 27 could be reduced when compared to controls because of the loss of pigmented dopaminergic neurons in the midbrain in PSP, similar to what has been shown in Parkinson's disease. 35 The difference observed between PSP and both controls and Alzheimer's dementia in the midbrain may, therefore, have been reduced because of these issues. These factors ultimately limit the diagnostic specificity of [ 
